# DexCom, Inc. (DXCM)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $29.41B  
**Price:** $75.36 (+0.79%)

> DexCom, Inc. is a leading medical technology company specializing in continuous glucose monitoring (CGM) systems for diabetes management. Its primary products deliver real-time glucose readings through small, wearable sensors that provide accurate, personalized data to users, simplifying daily monitoring and decision-making for people with diabetes. The company's CGM platforms integrate seamlessly with smartphones and insulin delivery devices, enabling features like customizable alerts, trend analysis, and sharing capabilities for caregivers and healthcare providers. DexCom, Inc. focuses on advancing glucose biosensing technology to enhance patient outcomes across all age groups, from children to adults. Its solutions support healthcare professionals in clinical settings and empower individuals with actionable insights for better glycemic control. Founded in 1999 and headquartered in San Diego, California, DexCom, Inc. plays a vital role in the diabetes care sector, driving innovation in remote monitoring and connected health ecosystems within the broader medical device industry.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $4.66B | $2.80B | $912M | $836M | $2.09 |
| 2024 | $4.03B | $2.44B | $600M | $576M | $1.42 |
| 2023 | $3.62B | $2.29B | $598M | $542M | $1.30 |
| 2022 | $2.91B | $1.88B | $391M | $341M | $0.82 |
| 2021 | $2.45B | $1.68B | $266M | $217M | $0.39 |
| 2020 | $1.93B | $1.28B | $300M | $494M | $1.26 |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $6.34B | $3.59B | $2.75B | $918M | $1.37B |
| 2024 | $6.48B | $4.38B | $2.10B | $606M | $1.36B |
| 2023 | $6.26B | $4.20B | $2.07B | $566M | $2.57B |
| 2022 | $5.39B | $3.26B | $2.13B | $642M | $1.35B |
| 2021 | $4.93B | $2.89B | $2.04B | $1.05B | $2.14B |
| 2020 | $4.29B | $2.46B | $1.83B | $818M | $1.82B |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $1.48B | -$364M | $1.08B |
| 2024 | $1.06B | -$359M | $631M |
| 2023 | $694M | -$237M | $512M |
| 2022 | $793M | -$365M | $305M |
| 2021 | $465M | -$389M | $53M |
| 2020 | $446M | -$199M | $277M |

Source: [CompaniesByCap](https://companiesbycap.com/company/DXCM)